Valbiotis SA
PAR:ALVAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Valbiotis SA
Long-Term Debt
Valbiotis SA
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Valbiotis SA
PAR:ALVAL
|
Long-Term Debt
€3.1m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Long-Term Debt
€186.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Long-Term Debt
€3.5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
-2%
|
|
|
Inventiva SA
PAR:IVA
|
Long-Term Debt
€51.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Long-Term Debt
$5.4m
|
CAGR 3-Years
68%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Long-Term Debt
€52.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
90%
|
|
Valbiotis SA
Glance View
Valbiotis SA develops products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
See Also
What is Valbiotis SA's Long-Term Debt?
Long-Term Debt
3.1m
EUR
Based on the financial report for Dec 31, 2025, Valbiotis SA's Long-Term Debt amounts to 3.1m EUR.
What is Valbiotis SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-9%
Over the last year, the Long-Term Debt growth was -12%. The average annual Long-Term Debt growth rates for Valbiotis SA have been -18% over the past three years , -9% over the past five years .
